| 序号 | 专利名 | 申请号 | 申请日 | 公开（公告）号 | 公开（公告）日 | 发明人 |
|---|---|---|---|---|---|---|
| 121 | HEME CHOLINE ESTERS AND USES THEREOF | US11958671 | 2007-12-18 | US20090155829A1 | 2009-06-18 | Thomas Pirrie Treynor; Anup Sood; Sean Richard Dinn |
| Methods of activating an apo-peroxidase are provided. The methods include the steps of providing a solution comprising an apo-peroxidase and a heme choline ester, hydrolyzing the heme choline ester with a choline esterase, and converting the apo-peroxidase to active peroxidase. The methods disclosed herein also provide for detecting the presence of an analyte in a sample. The methods include providing a binder capable of specifically binding the analyte wherein the binder is attached to a solid surface, applying the sample to the solid surface under conditions that permit binder-analyte binding, adding a choline esterase-conjugated binder that binds to the analyte, adding an apo-peroxidase, a heme choline ester, a peroxide, and a peroxide-activated signal generator, and detecting the signal produced by the peroxide-activated signal generator. An associated kit and components are also provided. | ||||||
| 122 | Phenylpiperazine cycloalkanol derivatives and methods of their use | US10963458 | 2004-10-12 | US07531543B2 | 2009-05-12 | Paige Erin Mahaney; Eugene John Trybulski; Lori Krim Gavrin; An Thien Vu |
| The present invention is directed to phenylpiperazine cycloalkanol derivatives, compositions containing these derivatives, and methods of their use for the prevention and treatment of conditions ameliorated by monoamine reuptake including, inter alia, vasomotor symptoms (VMS), sexual dysfunction, gastrointestinal and genitourinary disorders, chronic fatigue syndrome, fibromylagia syndrome, nervous system disorders, and combinations thereof, particularly those conditions selected from the group consisting of major depressive disorder, vasomotor symptoms, stress and urge urinary incontinence, fibromyalgia, pain, diabetic neuropathy, and combinations thereof. | ||||||
| 123 | Cycloalkylamine derivatives as NK-1/SSRI antagonists | US11183699 | 2005-07-18 | US07494986B2 | 2009-02-24 | Yong-Jin Wu; Huan He |
| The present disclosure relates to chemical compounds and their use in human therapy. A specific embodiment relates to compounds of Formula (I) or an isomer, a pharmaceutically acceptable salt or solvate thereof and pharmaceutically acceptable formulations comprising said compounds useful for the treatment or prevention of conditions mediated by tachykinins and/or selective inhibition of serotonin reuptake transporter protein. The compounds act as dual NK-1 antagonists and selective serotonin reuptake inhibitors. | ||||||
| 124 | Beta-Substituted Porphyrins | US11576690 | 2005-10-10 | US20080283122A1 | 2008-11-20 | Wayne Mason Campbell; David Leslie Officer; Michael Graetzel; Md. Khaja Nazeeruddin |
| The invention relates to ÿ-substituted porphyrins, methods for their synthesis, and their use in the preparation of photoelectric materials. In particular, the invention relates to solid state photoelectric devices, including solar cells and photodetectors, incorporating these photoelectric materials, with improved photon-to-current conversion efficiencies. | ||||||
| 125 | Glycosylated Carboranylporphyrins and Uses Thereof | US11746957 | 2007-05-10 | US20080279781A1 | 2008-11-13 | Michiko Miura; Haitao Wu |
| The present invention is directed to low toxicity boronated compounds and methods for their use in the treatment, visualization, and diagnosis of tumors. More specifically, the present invention is directed to low toxicity glycosylated carborane-containing 5,10,15,20-tetraphenylporphyrin compounds and methods for their use particularly in boron neutron capture therapy (BNCT) and photodynamic therapy (PDT) for the treatment of tumors of the brain, and head and neck. The invention is also directed to using these glycosylated carborane-containing tetraphenylporphyrin compounds in methods of tumor imaging and/or diagnosis such as MRI, SPECT, or PET. | ||||||
| 126 | Backbone-substituted bifunctional DOTA ligands, complexes and compositions thereof, and methods of using same | US10525673 | 2003-09-05 | US07368100B2 | 2008-05-06 | Martin W. Brechbiel; Hyun-Soon Chong |
| Backbone-substituted 1,4,7,10-tetraaza cyclododecane-N,N′,N″,N′″-tetraacetic acid compounds, metal complexes thereof, compositions thereof, conjugates thereof, and methods of use in diagnostic imaging and treatment of a cellular disorder. | ||||||
| 127 | Preparation of metallotexaphyrins | US10537379 | 2003-11-24 | US20070287829A1 | 2007-12-13 | Douglas Cary; Lei Fu; Tarak Mody |
| The present invention provides a process for replacing a metal cation, M1, from a compound of Formula L | ||||||
| 128 | Contrast Agents for Magnetic Resonance Imaging | US11547088 | 2005-03-31 | US20070218010A1 | 2007-09-20 | Jens Hasserodt |
| The invention relates to contrast agents for magnetic resonance imaging comprising a chelating ligand and a transition metal ion, said ligand carrying a substituent capable of reacting chemically or biochemically with a target substance while bringing about a change in the spin state. | ||||||
| 129 | Light-harvesting discotic liquid crystalline porphyrins and metal complexes | US11638163 | 2006-12-13 | US20070152189A1 | 2007-07-05 | Quan Li; Xiaoli Zhou |
| Novel discotic liquid crystalline porphyrins and discotic liquid crystalline metal complexes, methods for their preparation, and device fabrication are disclosed. Materials with partially perfluorinated alkyl group in the peripheral chains show a strong tendency towards the formation of homeotropic alignment. These compounds are capable of being used as high-efficiency photovoltaic materials, organic semiconducting materials, and organic light emitting materials. | ||||||
| 130 | Cascade polymer complexes, process for their production and pharmaceutical agents containing said complexes | US10686717 | 2003-10-17 | US07211241B2 | 2007-05-01 | Heribert Schmitt-Willich; Johannes Platzek; Bernd Radüchel; Andreas Mühler; Thomas Frenzel |
| Described are new cascade polymer complexes, compositions containing them and use of the complexes in diagnosis and therapy, particularly for magnetic resonance imaging and computer tomography imaging. | ||||||
| 131 | Process for labeling a nucleic acid | US09736151 | 2000-12-15 | US06902891B2 | 2005-06-07 | Ali Laayoun; Lionel Menou; Christelle Tora; Aloke R. Banerjee; Michael M. Becker; Kenneth A. Browne; Matthew C. Friedenberg; Fred F. Hajjar |
| A process of fragmenting and labeling a synthetic or natural nucleic acid, comprising the steps of providing a mixture containing a nucleic acid, a labeling agent containing a detectable label, and at least one multivalent metal cation in a substantially aqueous solution; chemically fragmenting the nucleic acid in the mixture to produce a multiplicity of nucleic acid fragments; and attaching at least one label to at least one of the nucleic acid fragments to produce a detectably labeled nucleic acid fragment. | ||||||
| 132 | Process for the preparation of an N-alkyl or N-aryl carbamoyl derivative | US09815268 | 2001-03-23 | US20020028932A1 | 2002-03-07 | Jacobus A. Loontjens; Bartholomeus J.M. Plum |
| The invention relates to a process for the preparation of an N-alkyl or N-aryl carbamoyl derivative in which an amine is contacted with a carbonic acid derivative according to the general formula: 1 where fragments X in the form of XH are a lactam, oxime, imide or triazole. In particular the invention relates to the preparation of a blocked isocyanate according to a process in which no isocyanate is used. The invention also relates to the use of the N-alkyl or N-aryl carbamoyl derivative prepared according to the process according to the invention in a coating. | ||||||
| 133 | Process for the preparation of macrocyclic metalloprotease inhibitors | US09919564 | 2001-07-31 | US20020013459A1 | 2002-01-31 | Roberta L. Dorow; Silvio Campagna; Pasquale N. Confalone; Fuqiang Jin; Zhe Wang |
| The present invention relates to processes for the preparation of macrocyclic molecules containing anti-succinate residues which inhibit metalloproteinases such as aggrecanase, and the production of tumor necrosis factor (TNF). The anti-succinates are formed by an Ireland Claisen rearrangement of a silyl ketene acetal which proceeds with high stereoselectivity. | ||||||
| 134 | Fungicidal trifluorophenyl-triazolopyrimidines | US273151 | 1999-03-19 | US6117865A | 2000-09-12 | Klaus-Juergen Pees |
| The novel compounds of formula I: ##STR1## (R.sup.1, R.sup.2 and Hal are defined in the specification) show selective fungicidal activity. The new compounds are processed with carriers and adjuvants to form fungicidal compositions. | ||||||
| 135 | Dichelants | US898376 | 1997-07-22 | US5972307A | 1999-10-26 | Joan Carvalho; Alan D. Watson; Jere D. Fellmann; Michael Koo |
| This invention relates to dichelants, in particular compounds having two macrocyclic chelant groups linked by a bridge containing an ester or amide bond, especially compounds of formula Vb ##STR1## (wherein each X which may be the same or different is NZ, O or S, at least two Xs being NZ;each Z is a group R.sup.1 or a group CR.sup.1.sub.2 Y, at least one Z, and preferably 2 or 3 Zs, on each macrocyclic ring being a group CR.sup.1.sub.2 Y;each Y is a group CO.sub.2 H, PO.sub.3 H, SO.sub.3 H, CONR.sup.1.sub.2, CON(OR.sup.1)R.sup.1, CNS or CONR.sup.1 NR.sup.1.sub.2, preferably COOH;m is 0 or 1 or 2, preferably 1; each n is 2 or 3, preferably 2; q is 1 or 2, preferably 1;each R.sup.1 which may be the same or different is a hydrogen atom or an alkyl group optionally substituted by one or more hydroxy and/or alkoxy groups;and D is a bridging group having a molecular weight of less than 1000, preferably less than 500, joining two macrocyclic rings via at least one amide or ester bond) and salts and metal chelates thereof. | ||||||
| 136 | Tricyclic benzazepine vasopressin antagonists | US639014 | 1996-04-24 | US5869483A | 1999-02-09 | Jay Donald Albright; Fuk-Wah Sum |
| Tricyclic compounds of the general Formula I: ##STR1## as defined herein which exhibit antagonist activity at V.sub.1 and/or V.sub.2 receptors and exhibit in vivo vasopressin antagonist activity, methods for using such compounds in treating diseases characterized by excess renal reabsorption of water, and processes for preparing such compounds. | ||||||
| 137 | Chelant moieties linked to an aryl moiety by an interrupted alkylene linker | US727594 | 1997-01-17 | US5798089A | 1998-08-25 | John Varadarajan; Alan David Watson; Arne Berg |
| The invention provides amphiphilic compounds of the formula (I) Ch--(--L--Ar--(--AH).sub.n).sub.m (where Ch is a hydrophilic chelant moiety or a salt or a chelate thereof); each L is an optionally oxo substituted C.sub.2-25 -alkylene linker wherein at least one CH.sub.2 moiety is replaced by a group X.sup.1 (e.g. L may include a chain sequence, an X.sup.1 (CH.sub.2 CH.sub.2 X.sup.1).sub.u (where u is a positive integer) such as X.sup.1 (CH.sub.2 CH.sub.2 X.sup.1).sub.u, CH.sub.2 X.sup.1 CH.sub.2 CH.sub.2 X.sup.1 CH.sub.2 CH.sub.2 X.sup.1, CH.sub.2 X.sup.1 CH.sub.2 CH.sub.2 X.sup.1 CH.sub.2 CH.sub.2 X.sup.1 CH.sub.2 CH.sub.2 X.sup.1, etc.), and wherein L is optionally interrupted by a metabolizable group M but with the provisos that the terminus of L adjacent Ch is CH.sub.2 and that the terminus of L adjacent Ar is X.sup.1 or a CH.sub.2 group adjacent or separated by one CH.sub.2 from a group X.sup.1 (thus, for example the L--Ar linkage may be L.sup.1 --X.sup.1 --Ar, L.sup.1 --CH.sub.2 --Ar, L.sup.1 --X.sup.1 CH.sub.2 --Ar or L.sup.1 --X.sup.1 CH.sub.2 CH.sub.2 --Ar, where L.sup.1 is the residue of L; each Ar is an aryl ring optionally substituted by or having fused thereto a further aryl ring; each AH is a protic acid group, preferably an oxyacid, e.g. a carbon, sulphur or phosphorus oxyacid or a salt thereof; each X.sup.1 is O, S, NR.sup.1 or PR.sup.1, preferably no more than 3 X.sup.1 groups being present in L; each R.sup.1 is hydrogen, alkyl or aryl; and m and n are positive integers, m being for example 1 to 4, especially 1 or 2 and n being for example, 1, 2 or 3) which are especially suited for use in diagnostic imaging of the hepatobiliary system. | ||||||
| 138 | Macrocyclic complexing agents and targeting immunoreagents useful in therapeutic and diagnostic compositions and methods | US392614 | 1995-02-22 | US5760191A | 1998-06-02 | Robert A. Snow; Daniel J. Delecki; Chandra R. Shah |
| A metal chelate comprising a compound having the following formula and one or more metal ions which metal ions are a radionucleotide or a paramagnetic metal ion: ##STR1## | ||||||
| 139 | Tricyclic benzazepine vasopressin antagonists | US662546 | 1996-06-13 | US5693635A | 1997-12-02 | Jay Donald Albright; Marvin Fred Reich |
| Tricyclic compounds of the general Formula I: ##STR1## as defined herein which exhibit antagonist activity at V.sub.1 and/or V.sub.2 receptors and exhibit in vivo vasopressin antagonist activity, methods for using such compounds in treating diseases characterized by excess renal reabsorption of water, and processes for preparing such compounds. | ||||||
| 140 | Pyridobenzoxazepine and pyridobenzothiazepine vasopressin antagonists | US637908 | 1996-04-25 | US5686445A | 1997-11-11 | Jay Donald Albright; Xuemei Du |
| Tricyclic compounds of the general Formula I: ##STR1## as defined herein which exhibit antagonist activity at V.sub.1 and/or V.sub.2 receptors and exhibit in vivo vasopressin antagonist activity, methods for using such compounds in treating diseases characterized by excess renal reabsorption of water, and processes for preparing such compounds. | ||||||
QQ群二维码
意见反馈
意见反馈